Navigating COVID-19 Challenges to Provide Optimal Cancer Care
Gilberto De Lima Lopes, MD, discusses the impact of COVID-19 on his practice and how he is coping with the changes caused by the pandemic.
Transplant Considerations in Hematologic Malignancies in Light of COVID-19
Naval G. Daver, MD, discusses the impact of COVID-19 on stem cell transplant for patients with hematologic malignancies and other measures put into place to prevent patients from infection.
Expert Highlights Benefit of PARP Inhibitors in BRCA+ Breast Cancer and Potentially Beyond
Melinda L. Telli, MD, discusses the role of PARP inhibition in the treatment of patients with breast cancer who harbor the BRCA mutations and ongoing research efforts seeking to expand their use beyond this setting.
Novel Therapies Expand Options in Melanoma, But Surgery Retains Role
Omid Hamid, MD, discusses emerging treatment approaches, the role of surgery, and ongoing research efforts in melanoma.
Stem Cell Mobilization Strategies Call for Careful Consideration in Myeloma
Shaji Kumar, MD, discusses the role of stem cell transplant in multiple myeloma, different techniques for stem cell mobilization, and remaining challenges faced with this modality.
Managing Treatment Toxicity in CML and MPNs
Jorge E. Cortes, MD, discusses managing treatment toxicities to optimize therapeutic outcomes in patients with CML and MPNs.
COVID-19 Causes Shifts in Clinical Trial Practices
Shilpa Gupta, MD, discusses the modifications made to patient care in light of the COVID-19 pandemic, the hurdles faced with clinical trials during this time, and some of the ways in which her institution is facing the virus-related challenges head-on.
COVID-19 Challenges Change Oncology Practice
Suresh S. Ramalingam, MD, FASCO, discusses the adjustments being made in cancer care due to the rapid spread of COVID-19 and treatments under development.
ADCs and Other Novel Agents Boost HER2+ Breast Cancer Paradigm
Chau T. Dang, MD, discusses recent treatment breakthroughs and emerging agents in HER2-positive breast cancer.
Cabozantinib Combinations Generate Excitement in RCC
Rana R. McKay, MD, discusses the evolving role of cabozantinib in the renal cell carcinoma treatment paradigm and the research being done examining novel combinations.
Community Oncologist Underscores Importance of Education and Collaboration
Derek Thomas, MD, discusses his experience as a community oncologist and some challenges faced in practice.
Inclusion of Geriatric Populations in Breast Cancer Research Needed to Improve Care
Enrique Soto Pérez de Celis, MD, MSc, discusses some of the challenges of treating geriatric patients with breast cancer, emerging treatment options for this patient population, and recommendations for treating older patients.
MRD Assessment Gains Momentum in Hematologic Malignancies
Jerald P. Radich, MD, discusses the growing importance of MRD assessment in the treatment paradigm for patients with hematologic malignancies.
Borghaei Shares Long-Term Implications of COVID-19 on Cancer Care
Hossein Borghaei, DO, MS, discusses the impact of COVID-19 on clinical practice and projected how the virus will change practice for the better in the long term.
Pennell Shares Best Practices for Molecular Testing in Lung Cancer
Nathan Pennell, MD, PhD, offers strategies regarding molecular testing in patients with lung cancer and how to address treatment if patients are symptomatic and molecular testing results are unavailable.
Outpatient CAR T-Cell Therapy Found Safe, Effective in Large B-Cell Lymphoma
Carlos R. Bachier, MD, discusses the use of CAR T-cell therapy in the outpatient setting. He also shared insight on the evolving paradigm of graft-versus-host disease.
Optimal Management Needed for Blood Count Recovery Following CAR T-Cell Therapy
Tania Jain, MBBS, discusses blood count recovery in patients with hematology malignancies who receive CAR T-cell therapy.
Racial Disparities Reported With Quality of Care in Endometrial Cancer
Jason D. Wright, MD, discusses the findings of this trial and how practice can shift to decrease the gap between African-American and white patients with endometrial cancer.
Plasma-Based TMB May Predict Pembrolizumab Response in NSCLC
Charu Aggarwal, MD, MPH, discusses the design and findings of an analysis examining the role of TMB as a predictive biomarker for pembrolizumab-based therapy in NSCLC.
Belantamab Mafodotin Emerging as Novel Option for Relapsed/Refractory Myeloma
Sagar Lonial, MD, FACP, discusses the encouraging activity with the BCMA-targeted agent belantamab mafodotin in multiple myeloma.
Building On Immunotherapy, Preventing Acquired Resistance Are Next Steps in Lung Cancer Research
David P. Carbone, MD, PhD, discusses advances in immunotherapy and targeted therapy in non–small cell lung cancer and ongoing research efforts focused on acquired resistance to available therapies.
Proton Therapy Offers More Precision in Lung Cancer, But Lacks Accessibility
Terence T. Sio, MD, MS, discusses the utility of proton therapy in lung cancer.
Improvements Needed for Adjuvant Therapy in RCC
Che-Kai Tsao, MD, discusses the current unmet needs in adjuvant therapy for patients with renal cell carcinoma and how current research is addressing such challenges.
Treatments for Oncogenic-Driven Lung Cancer Continue to Expand
Anastasios Dimou, MD, discusses available and emerging treatment options and approaches for patients with oncogenic-driven lung cancer.
NY-ESO-1, MAGE-A4 Among Key Targets in Sarcoma Research
Neeta Somaiah, MD, discusses ongoing research in the field of sarcoma.
Key Advances in Sarcoma Lead to More Personalized Medicine Efforts
Jonathan C. Trent, MD, PhD, discusses recent advances and ongoing research in the field of soft tissue sarcoma.
Multidisciplinary Approach Required for Pulmonary Hypertension in Myelofibrosis
Juan C. Lopez-Mattei, MD, FACC, FASE, FSCCT, FSCMR, discusses the findings of the retrospective analysis of pulmonary hypertension in patients with myelofibrosis and their impact on clinical practice.
Grivas Shares Insight on Biomarker Research, Combo Strategies in Prostate Cancer
Petros Grivas MD, PhD, discusses biomarker-driven and combination research in metastatic castration-resistant prostate cancer.
Early-Stage Pancreatic Cancer Paradigm Needs Refining
Matthew H.G. Katz, MD, FACS, discusses data with neoadjuvant therapy and ongoing research in pancreatic cancer.
BiTEs and CAR T Cells Burst Through ALL Paradigm
Mohammad Maher Abdul-Hay, MD, discusses current standards for the treatment of patients with acute lymphocytic leukemia.
Adding Navitoclax to Ruxolitinib Doubles Spleen Volume Reductions for Myelofibrosis
MRD Positivity Correlates With Allogeneic Transplant Benefits in NPM1-Mutated AML
Orca-T Shows High Survival Rates in Intermediate-/High-Risk Myelodysplastic Syndrome
Orca-T Demonstrates Feasibility in Older Patients With Hematologic Malignancies
2 Clarke Drive Cranbury, NJ 08512